Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Phase 1, Open-label, Two-stage, Randomized Trial to Assess the Safety, Tolerability, and Biodistribution of [177Lu]Lu-ABY-271 in Tumors and Critical Organs in Subjects With HER2-positive Metastatic Breast Cancer

NCT07081555 is registered in ClinicalTrials.gov with Affibody as lead sponsor.

NCT NCT07081555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07081555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Phase 1, Open-label, Two-stage, Randomized Trial to Assess the Safety, Tolerability, and Biodistribution of [177Lu]Lu-ABY-271 in Tumors and Critical Organs in Subjects With HER2-positive Metastatic Breast Cancer
Lead sponsor
Affibody
Phase
Phase 1
Overall status
Recruiting
Start date
October 6, 2025
Completion date
June 1, 2028
Enrollment
21 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

her2 + breast cancer, metastatic breast cancer